FDA accepts Regeneron’s EYLEA Injection sBLA for new eye treatment
Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review of an sBLA is ten months from submission, with a target action date of
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
Metabolon has signed several research collaboration and licensing agreements with Patia Biopharma related to use of Metabolon’s Quantose IR technology, a blood test for prediabetes that reflects insulin
DGF is an early and serious complication of organ transplantation that is characterized by the failure of a transplanted organ to function normally immediately following transplantation. In patients